|
 |
| ORIGINAL ARTICLE |
|
|
|
| Year : 2013 | Volume
: 23
| Issue : 3 | Page : 180-183 |
| |
Serum cystatin C as a marker of renal function in detection of early acute kidney injury
M. S. N. Murty1, UK Sharma2, VB Pandey1, SB Kankare1
1 Department of Medicine and Nephrology, INHS Asvini, Colaba, Mumbai, India
2 Department of Medicine and Nephrology, Army Hospital (R and R), Delhi, India
| Date of Web Publication | 14-May-2013 |
Correspondence Address:
M. S. N. Murty
Department of Medicine and Nephrology, INHS Asvini, Colaba, Mumbai - 400 005, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0971-4065.111840
In patients with acute kidney injury (AKI), serum creatinine level does not increase until moderate to severe reduction in glomerular filtration rate (GFR) occurs. Thus its use for estimating GFR in early AKI delays detection of kidney damage and making important therapeutic decisions. Moreover, serum cystatin C is not affected by gender, age, race, and muscle mass and also does not suffer from lag period for its rise in early AKI. We studied 200 healthy subjects and 130 AKI patients over a period of 2 years at a tertiary care hospital. Serum creatinine and serum cystatin C were studied and analyzed in relevance to early AKI. We found that 56.2% of patients of AKI group had normal levels of serum creatinine in early phase, while all patients had elevated serum cystatin C at same time. Multiple logistic regression analysis revealed cystatin C-based GFR reflecting decline in GFR with worsening AKI in better than creatinine-based GFR. Serum cystatin C is a better marker of renal function in early stages of AKI and is less affected by age, gender, muscle mass, and ethnicity. Its use helps in early therapeutic intervention and possibly favorable outcome.
Keywords: Acute kidney injury, serum cystatin C, serum creatinine
How to cite this article:
Murty M, Sharma U K, Pandey V B, Kankare S B. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian J Nephrol 2013;23:180-3 |
How to cite this URL:
Murty M, Sharma U K, Pandey V B, Kankare S B. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian J Nephrol [serial online] 2013 [cited 2022 Mar 5];23:180-3. Available from: https://www.indianjnephrol.org/text.asp?2013/23/3/180/111840 |
| Introduction | |  |
Acute kidney injury (AKI) is characterized by rapid decline in glomerular filtration rate (GFR). GFR is presently being monitored by serum creatinine concentration and calculated creatinine clearance using Cockcroft and Gault equation or Modification of Diet in Renal Disease study (MDRD) formula. [1],[2],[3] However, serum creatinine does not increase until the GFR has moderately decreased (about 40 ml/min/1.73 m 2 ). This insensitivity for small to moderate decreases in GFR in creatinine blind GFR area (40-70 ml/min/1.73 m 2 ) gives a false sense of security and leads to late detection of kidney damage. All this makes serum creatinine less reliable for making therapeutic decisions in critically ill patients, such as decision to change nephrotoxic drugs or measures to increase renal perfusion.
Serum cystatin C is a non-glycosylated, 13.3-kDa protein belonging to cystatin protease inhibitors. It has shown promise as a replacement for serum creatinine in estimation of GFR. [4],[5] After glomerular filtration, it is fully catabolized in the proximal renal tubule and is not returned to blood. Concentration of serum cystatin C is not affected by gender, age, race, protein intake, and muscle mass, unlike serum creatinine. When GFR decreases, cystatin C level begins to rise proportionately.
In this study, we studied serum creatinine and serum cystatin C levels in AKI to establish its relevance in the early period of AKI.
| Materials and Methods | | |
The study was carried out from September 2008 to September 2010 at a tertiary care hospital. The study group consisted of 200 healthy subjects and 130 patients of AKI. After obtaining an informed consent, a screening questionnaire was filled to collect information such as age, gender, height, weight, comorbidities, personal history, drug history, presenting complaints, and laboratory investigations. A detailed physical examination was carried out.
The serum cystatin C and serum creatinine values were measured simultaneously and analyzed. In the AKI study group, they were taken within 24 hours of onset of injury. The "RIFLE" criteria were used for defining the AKI, and the stages "risk" and "injury" constituted the "early AKI."
GFR was estimated using the Cockcroft-Gault formula for creatinine clearance and Larsson formula for cystatin C-based GFR.
Larsson formula: eGFR = 77.24 × cystatin C−1.2623
The gold standard for measuring GFR viz. inulin clearance, urinary clearance of exogenous radioactive markers ( 125 I-iothalamate and 99m Tc-DTPA (diethylene-triamine -pentaacetate)), was not used in this study due to practical limitations.
Statistical analysis was performed using appropriate statistical tests and P value less than 0.05 was considered significant.
| Results | | |
The characteristics of our study population are given in [Table 1]. | Table 1: Demographic and biochemical characteristics of study population
Click here to view |
Serum cystatin C had lower standard deviation (1.1) and serum creatinine had higher standard deviation (1.8) in AKI indicating lesser variability of serum cystatin C.
The variation of serum creatinine was significantly greater than that of serum cystatin C in both groups. The standard deviation of serum creatinine (0.23) is double that of serum cystatin C (0.12) in the healthy group, which indicates a wide fluctuation in serum creatinine compared to serum cystatin C in healthy population too.
Although the correlation between serum creatinine and serum cystatin C was significant in both groups, a high strength of correlation was observed in the AKI group [Table 2]. This implies that small changes in serum creatinine are best reflected by a proportionate rise in serum cystatin C in AKI, especially at lower values.
In our study, it was found that in the AKI group majority (56.2%) had normal creatinine values (0.9-1.4 mg/dl). This subset was in "creatinine blind" range where serum creatinine values are normal with elevated cystatin C levels. All 130 patients with AKI had deranged cystatin C levels [Table 3], [Figure 1]. This confirms the finding that serum cystatin C is elevated much before serum creatinine levels start rising and does not suffer from the disadvantage of creatinine blind area. In this way it helps for early detection of kidney injury. | Figure 1: Distribution of serum creatinine and serum cystatin C in acute kidney injury
Click here to view |
 | Table 3: Distribution of serum creatinine and serum cystatin C in acute kidney injury
Click here to view |
Multiple logistic regression applied to GFR calculated by Cockroft-Gault using serum creatinine and GFR-calculated serum cystatin C in AKI group gave a correlation coefficient (R) of 0.822 [Table 4]. This showed a good positive correlation between creatinine-based GFR and cystatin C-based GFR. Correlation coefficient of creatinine-based GFR is -0.00213 and that of cystatin C-based GFR is -0.00673. Cystatin C-based GFR resulted in more negative correlation compared to creatinine-based GFR in the AKI group. It means cystatin C-based GFR reflects a decline in GFR with worsening AKI in a much better way compared to creatinine-based GFR. The P value was significant (P < 0.01) for both cystatin C- and creatinine-based GFR. | Table 4: Multiple logistic regression for glomerular filtration rate using serum creatinine and cystatin C in acute kidney injury patients
Click here to view |
Thus in the AKI group, cystatin C-based GFR was better compared to creatinine-based GFR in early detection of worsening clinical status. This suggests the utility of serum cystatin C over serum creatinine in predicting early decline in GFR and thereby helping in early therapeutic intervention.
| Discussion | | |
Creatinine production changes significantly according to the muscle mass of the body and dietary factors. Creatinine is filtered by the glomeruli, and also secreted by the renal tubules. This tubular secretion contributes approximately 20% of the total creatinine excretion by the kidney and it can increase as GFR decreases. All of these factors explain why serum creatinine concentration may not be a good parameter for accurate determination of GFR, especially at lower rates. [6]
Cystatin C production in the body is a stable process that is not influenced by renal conditions, increased protein catabolism, or dietetic factors. Moreover, it does not change with age or muscle mass like creatinine does. Its biochemical characteristics allow free filtration in the renal glomerulus, and subsequent metabolism and reabsorption by the proximal tubule. For these reasons, serum cystatin C has been suggested to be an ideal endogenous marker of GFR. [7],[8],[9] However, few studies demonstrate that older age is independently associated with higher serum cystatin C levels after adjusting for creatinine clearance. [10]
Serum creatinine had higher standard deviation the, serum cystatin C in both subgroups AKI, and healthy, respectively. The variation of serum creatinine is significantly greater than that of serum cystatin C in both the groups. Serum creatinine level increases with increase in muscle mass and protein intake, whereas tubular secretion increases with fall in GFR, blunting its rise. Thus serum creatinine concentration may not be a good parameter for accurate determination of GFR, especially at lower rates. This proves superiority of serum cystatin C over serum creatinine in AKI. Similar observations were found in many studies, especially in a meta-analysis by Dharnidharka et al, [11] and Kyhse-Andersen et al. [4]
In the AKI group, more than half the patients (56.2%) had normal creatinine values, but they had elevated cystatin C and were in creatinine blind area. Moreover, all AKI patients had deranged cystatin C. This confirms the finding that serum cystatin C is elevated much before serum creatinine levels start rising. Serum cystatin C has a higher sensitivity in identifying early kidney dysfunction, which is missed by relying on serum creatinine alone.
The creatinine blind area is the range between 40 and 70 ml/min/1.73 m 2 where a decrease in GFR starts to occur. Early reduction in GFR will not be shown up with creatinine testing, whereas cystatin C will show a true positive reduction in GFR. The creatinine test will give a false negative result. The cystatin C test will give a true positive. Cystatin C does not have a blind area. Early diagnosis of AKI based on serum cystatin C helps in timely intervention to have favorable outcome. Cystatin C indicates a more real-time functional state of the kidney and without the lag period as in the case with creatinine measurement. Cystatin C-based GFR gives a direct and accurate measurement of GFR independent of age and muscle mass. [12],[13],[14]
GFR in critically ill individuals can change rapidly because of, for example, renal hypoperfusion secondary to shock or the use of nephrotoxic agents. Despite this, it is not uncommon to see changes in the serum creatinine for up to several days until the stabilization phase is reached. This may also explain the poor diagnostic usefulness of serum creatinine in early hours of AKI, as seen in our study compared with that In other studies. [8],[15] The delay that usually exists between the decline in GFR and that in serum creatinine makes the latter test poorly reliable for making therapeutic decisions in critically ill patients, such as a decision to change nephrotoxic agents or to increase renal perfusion.
This study has some limitations. This is a cross-sectional study with assessment carried out at a single point of time; a old standard comparison for estimation of GFR viz. inulin clearance, urinary clearance of exogenous radioactive markers ( 125 I-iothalamate and 99m Tc-DTPA), has not been used in this study due to practical constraints, and we used RIFLE criteria for defining the AKI instead of Acute Kidney Injury Network (AKIN) criteria as the current study uses eGFR which is not incorporated in the latter.
| Conclusion | | |
To conclude, serum cystatin C is a better marker of renal function in early stages of AKI and is less affected by age, gender, muscle mass, and ethnicity. Use of serum cystatin C-based GFR may be more accurate and useful for early therapeutic intervention and possibly a favorable outcome.
| References | | |
| 1. | Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. 
|
| 2. | National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
|
| 3. | Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005;16:763-73.
|
| 4. | Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994;40:1921-6.
|
| 5. | Jung K, Jung M. Cystatin C: A promising marker of glomerular filtration rate to replace creatinine. Nephron 1995;70:370-1.
|
| 6. | Kim KE, Onesti G, Ramirez O, Brest AN. Creatinine clearance in renal disease. A reappraisal. Br Med J 1969;4:11.
|
| 7. | Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 2000;54:203-9.
|
| 8. | Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest 1998;58:585-92.
|
| 9. | Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-8.
|
| 10. | Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-21.
|
| 11. | Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002;40:221-6.
|
| 12. | Ahlström A, Tallgren M, Peltonen S, Pettilä V. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol 2004;62:344-50.
|
| 13. | Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003;18:2024-31.
|
| 14. | Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011;305:1545-52.
|
| 15. | Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000;36:29-34.
|
[Figure 1]
[Table 1], [Table 2], [Table 3], [Table 4]
| This article has been cited by | | 1 |
Glyphosate and AMPA exposure in relation to markers of biological aging in an adult population-based study |
|
| Charlotte Cosemans, Nicolas Van Larebeke, Bram G Janssen, Dries S Martens, Willy Baeyens, Liesbeth Bruckers, Elly Den Hond, Dries Coertjens, Vera Nelen, Greet Schoeters, Hans-Wolfgang Hoppe, Esther Wolfs, Karen Smeets, Tim S Nawrot, Michelle Plusquin | | International Journal of Hygiene and Environmental Health. 2022; 240: 113895 | | [Pubmed] | [DOI] | | | 2 |
Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility |
|
| Nimish Patel, Jill Blumenthal, Michael P. Dubé, Allison Hood, Robert Bolan, Sheldon Morris | | LGBT Health. 2022; | | [Pubmed] | [DOI] | | | 3 |
Treatment of Chronic Kidney Disease with Extracellular Vesicles from Mesenchymal Stem Cells and CD133+ Expanded Cells: A Comparative Preclinical Analysis |
|
| Dayane Mayumi Miyasaki, Alexandra Cristina Senegaglia, Sérgio Adriane Bezerra de Moura, Amanda Leitolis, Luiz Guilherme Achcar Capriglione, Letícia Fracaro, Lidiane Maria Boldrini Leite, Paulo Henrique Utumi, Felipe Yukio Ishikawa Fragoso, Fernando Meyer, Alejandro Correa, Paulo Roberto Slud Brofman | | International Journal of Molecular Sciences. 2022; 23(5): 2521 | | [Pubmed] | [DOI] | | | 4 |
Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients |
|
| Ingrida Stankute, Lina Radzeviciene, Ausra Monstaviciene, Rimante Dobrovolskiene, Evalda Danyte, Rasa Verkauskiene | | Medicina. 2022; 58(2): 218 | | [Pubmed] | [DOI] | | | 5 |
Cystatin and Glomerular Filtration Rate in Obese Versus Non-obese Adolescents |
|
| Azza Abd El-Shaheed, Nermine N. Mahfouz, Reham F. Fahmy, Mona A. Elabd, Hiba Sibaii, Salwa Refat El-Zayat, Mahitab I. El-Kassaby, Hagar H. Mourad | | Open Access Macedonian Journal of Medical Sciences. 2021; 9(B): 1453 | | [Pubmed] | [DOI] | | | 6 |
Potential therapeutic efficacy of pachymic acid in chronic kidney disease induced in rats: role of Wnt/ß-catenin/renin–angiotensin axis |
|
| Nahla N Younis, Hoda E Mohamed, Mohamed A Shaheen, Asmaa M Abdelghafour, Sally K Hammad | | Journal of Pharmacy and Pharmacology. 2021; | | [Pubmed] | [DOI] | | | 7 |
Detection of Renal Insufficiency in a Cohort of Patients With Beta-thalassemia Major Using Cystatin-C |
|
| Mona Hamdy, Iman Shaheen, Zinab M. El-Gammal, Yasmin M. Ramadan | | Journal of Pediatric Hematology/Oncology. 2021; 43(8): e1082 | | [Pubmed] | [DOI] | | | 8 |
Prediction of drug-induced kidney injury in drug discovery |
|
| Priyanka Kulkarni | | Drug Metabolism Reviews. 2021; 53(2): 234 | | [Pubmed] | [DOI] | | | 9 |
Correlation of Serum Cystatin C with Renal Function in Gout Patients with Renal Injury |
|
| Yanqun Wu, Shunhua Wang, Xiaoqing Xu | | Journal of Interferon & Cytokine Research. 2021; 41(9): 329 | | [Pubmed] | [DOI] | | | 10 |
Inactivation of Wnt/ß-catenin/renin angiotensin axis by tumor necrosis factor-alpha inhibitor, infliximab, ameliorates CKD induced in rats |
|
| Nahla N. Younis, Hoda E. Mohamed, Mohamed A. Shaheen, Asmaa M. Abdelghafour, Sally K. Hammad | | Biochemical Pharmacology. 2021; 185: 114426 | | [Pubmed] | [DOI] | | | 11 |
MDM2 inhibition improves cisplatin-induced renal injury in mice via inactivation of Notch/hes1 signaling pathway |
|
| X Luo, L Zhang, G-D Han, P Lu, Y Zhang | | Human & Experimental Toxicology. 2021; 40(2): 369 | | [Pubmed] | [DOI] | | | 12 |
Review of early circulating biomolecules associated with diabetes nephropathy – Ideal candidates for early biomarker array test for DN |
|
| Kok Ying Quan, Christina Gertrude Yap, Nowrozy Kamar Jahan, Naganathan Pillai | | Diabetes Research and Clinical Practice. 2021; 182: 109122 | | [Pubmed] | [DOI] | | | 13 |
Potential Value of TNF-a (–376 G/A) Polymorphism and Cystatin C (CysC) in the Diagnosis of Sepsis Associated Acute Kidney Injury (S-AK I) and Prediction of Mortality in Critically Ill patients |
|
| Hiba S Al-Amodi, Shimaa Abdelsattar, Zeinab A. Kasemy, Hanan M. Bedair, Hany S. Elbarbary, Hala F. M. Kamel | | Frontiers in Molecular Biosciences. 2021; 8 | | [Pubmed] | [DOI] | | | 14 |
Population Pharmacokinetics of Intravenous Amoxicillin Combined With Clavulanic Acid in Healthy and Critically Ill Dogs |
|
| Maria D. Vegas Cómitre, Stefano Cortellini, Marc Cherlet, Mathias Devreese, Beatrice B. Roques, Alain Bousquet-Melou, Pierre-Louis Toutain, Ludovic Pelligand | | Frontiers in Veterinary Science. 2021; 8 | | [Pubmed] | [DOI] | | | 15 |
Rapid Multianalyte Microfluidic Homogeneous Immunoassay on Electrokinetically Driven Beads |
|
| Pierre-Emmanuel Thiriet, Danashi Medagoda, Gloria Porro, Carlotta Guiducci | | Biosensors. 2020; 10(12): 212 | | [Pubmed] | [DOI] | | | 16 |
Elevated serum creatinine in the context of HIV – who is the culprit? Over-the-counter supplements vs. antiretrovirals |
|
| A Gill, KA Fernando | | International Journal of STD & AIDS. 2020; 31(14): 1411 | | [Pubmed] | [DOI] | | | 17 |
The role of specific biomarkers, as predictors of post-operative complications following flexible ureterorenoscopy (FURS), for the treatment of kidney stones: a single-centre observational clinical pilot-study in 37 patients |
|
| Stephen Fôn Hughes, Alyson Jayne Moyes, Rebecca May Lamb, Peter Ella-tongwiis, Christopher Bell, Ahmed Moussa, Iqbal Shergill | | BMC Urology. 2020; 20(1) | | [Pubmed] | [DOI] | | | 18 |
The French national protocol for Kennedy’s disease (SBMA): consensus diagnostic and management recommendations |
|
| Pierre-François Pradat, Emilien Bernard, Philippe Corcia, Philippe Couratier, Christel Jublanc, Giorgia Querin, Capucine Morélot Panzini, François Salachas, Christophe Vial, Karim Wahbi, Peter Bede, Claude Desnuelle | | Orphanet Journal of Rare Diseases. 2020; 15(1) | | [Pubmed] | [DOI] | | | 19 |
Safety of a Combined WB-EMS and High-Protein Diet Intervention in Sarcopenic Obese Elderly Men |
|
| Wolfgang Kemmler, Simon von Stengel, Matthias Kohl, Nicolas Rohleder, Thomas Bertsch, Cornel C. Sieber, Ellen Freiberger, Robert Kob | | Clinical Interventions in Aging. 2020; Volume 15: 953 | | [Pubmed] | [DOI] | | | 20 |
An ultrasensitive Cystatin C renal failure immunosensor based on a PPy/CNT electrochemical capacitor grafted on interdigitated electrode |
|
| Paula A.B. Ferreira, Maria C.M. Araujo, Cecília M. Prado, Ricardo A. de Lima, Blanca A.G. Rodríguez, Rosa F. Dutra | | Colloids and Surfaces B: Biointerfaces. 2020; 189: 110834 | | [Pubmed] | [DOI] | | | 21 |
Earlier Detection of Glomerular Dysfunction in ß-Thalassemia Major Patients |
|
| Waseem F. Al Tameemi, Zainab M. J. Altawry | | Thalassemia Reports. 2020; 10(1): 17 | | [Pubmed] | [DOI] | | | 22 |
A Meta-Analysis on the Performance of Cystatin C- versus Creatinine-based eGFR Equations in Predicting Vancomycin Clearance |
|
| Nor Asyikin Mohd Tahir, Shamin Mohd Saffian, Farida Hanim Islahudin, Abdul Halim Abdul Gafor, Mohd Makmor-Bakry | | Journal of Korean Medical Science. 2020; 35(37) | | [Pubmed] | [DOI] | | | 23 |
Cystatin and glomerular filtration rate equations in old renal transplant donors |
|
| Ahmed Y. Ali, Sahier O. Elkhashab | | The Egyptian Journal of Internal Medicine. 2019; 31(2): 185 | | [Pubmed] | [DOI] | | | 24 |
Assessment of renal function in Japanese children with malignancies using serum cystatin C |
|
| Nami Nakamura, Hiroyoshi Watanabe, Kazumi Okamura, Shoji Kagami | | The Journal of Medical Investigation. 2018; 65(3.4): 231 | | [Pubmed] | [DOI] | | | 25 |
Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development |
|
| Leonie van Meer,Matthijs Moerland,Adam F. Cohen,Jacobus Burggraaf | | British Journal of Clinical Pharmacology. 2014; 77(6): 947 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
|
Editorial Board
